Loading
companiesCompany
TORL BioTherapeutics
TORL BioTherapeutics is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing the antibody-drug conjugates TORL-1-23 (ixotatug vedotin) and TORL-5-700 in non-Hodgkin lymphoma and ovarian cancer.
Also called: TORL Biotherapeutics, LLC
Overview
TORL BioTherapeutics develops antibody-drug conjugates for cancer, drawing on a research partnership with the Slamon laboratory at UCLA. Its lead programme TORL-1-23 (ixotatug vedotin) targets claudin 6 in solid tumours and is in phase 2 for platinum-resistant ovarian cancer; TORL-5-700 is an earlier-stage ADC. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07439653 (phase 1/2, A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma), NCT06690775 (phase 2, CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.) and NCT07322094 (phase 1/2, CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemothera...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Culver City, California, US
Scorecard
All companies#77of 1244 companies, score 58
- approved products +18
- modalities +4
- regions +6
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 0 targets, 8,079 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
ApprovedPegylated recombinant granulocyte colony-stimulating factor
Pegfilgrastim · Neulasta
Pegfilgrastim (Neulasta) is a long-acting form of the growth factor G-CSF, given once per chemotherapy cycle to speed white cell recovery and prevent febrile neutropenia; one dose replaces about eleven daily filgrastim injections. Biosimilars have been sold since 2018 and the Onpro on-body injector delivers it automatically the day after chemotherapy; bone pain is the main side effect.
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
ApprovedCytotoxic chemotherapy (platinum)
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
Similar pages
- TrialREFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Shares Pegfilgrastim, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialRandomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Shares Pegfilgrastim, Paclitaxel / nab-paclitaxel.
- TrialNeoPACT
Shares Pegfilgrastim, Carboplatin.
- TechnologyGrowth factors: G-CSF and febrile neutropenia prevention
Shares CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer., Pegfilgrastim.
- TermInfection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination
cancers
drugs
ApprovedCytotoxic chemotherapy (platinum)
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane
ApprovedPegylated recombinant granulocyte colony-stimulating factor
Pegfilgrastim · Neulasta